Jeanny Aragon-Ching, MD, Inova Schar Cancer Institute
Advertisement
Articles by Jeanny Aragon-Ching, MD, Inova Schar Cancer Institute
Advertisement
Latest Updated Articles
Increased Survival Outcomes with Switch Maintenance in mUCPublished: August 26th 2020 | Updated:
Changing the Standard of Care in Metastatic Bladder CancerPublished: August 26th 2020 | Updated:
Safety Data from JAVELIN Bladder 100Published: August 26th 2020 | Updated:
Sequencing Considerations in mUC after Frontline IOPublished: August 26th 2020 | Updated:
Current Status of Therapy: Metastatic Urothelial CancerPublished: August 26th 2020 | Updated:
PD-L1 Expression in Metastatic Urothelial CancerPublished: August 26th 2020 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
2
Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma
3
FDA Underscores Risks Associated With DPD Deficiency and Capecitabine/5-FU Use in Cancer Care
4
FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL
5